Shares in Elan and Biogen Idec plunged on Monday as the firms suspended sales of new multiple sclerosis drug Tysabri after a patient's death in the US.Elan, once the biggest firm on the Irish stock exchange, was also expected to receive a boost, from the new product.On the New York Stock Exchange, shares in Ireland-based Elan lost 70% while US partner Biogen Idec shed 43%.- Shares in UK pharmaceutical firm Phytopharm closed down 19.84% at 151.5 pence on the London Stock Exchange on Monday, after it said a partner was set to pull out of a deal on an experimental Alzheimer's disease treatment.Tysabri was approved for use in the US last November and was widely tipped to become the world's leading multiple sclerosis treatment.The cases cited involved the use of both Tysabri and Avonex, Biogen Idec's existing multiple sclerosis drug."Most of the value in the company was in Tysabri," said Ian Hunter at Goodbody Stockbrokers in Dublin.